ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,539,326, issued on Feb. 3, was assigned to Novo Nordisk A/S (Bagsvaerd, Denmark).
"Methods for treating Alzheimer's disease using semaglutide" was invented by Charlotte Christine Thim Hansen (Soeborg, Denmark), Lotte Bjerre Knudsen (Jerslev, Denmark), Anna Secher (Koebenhavn, Denmark) and Daniel Vega Moller (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide."
The patent was filed on Dec. 12, 2024, under Application No. 18/979,068.
...